Bo dziaaj odmiennymi, lecz komplementarnymi mechanizmami w obrbie tej samej tkanki bony luzowej jelita
(PubMed) Booth SL, Golly I, Sacheck JM, et al
MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2
Preclinical and clinical studies demonstrate that co-administration of these peptides achieves superior reductions in bodyweight, appetite, and fasting glucose than either agent aloneachieving up to a 17% reduction in bodyweight in non-diabetic individuals and a 15.6% reduction in patients with type 2 diabetes over 2032 weeks
Do not disregard any medical advice you have received or delay in seeking it because of something you have read on our websites or associated materials
Cautions Keep in a cool and dry place, out of the reach and sight of children